Public Health

  • Read more: 4/25: Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies
    Article

    4/25: Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies

    By Adriana Benedict Universities Allied for Essential Medicines (UAEM)Boston-Wide Forum on Global Access Licensing of Biomedically Relevant Technologies Thursday, April 25th, 3-5pmCoffee and refreshments at 2:45pm; reception following the eventHarvard Medical School New Research Building – 77 Avenue Louis PasteurSeminar Room 1031 How do innovative medical technologies make their way to a global population, including…

  • Read more: Caplan et al. on Civil Commitment for Alcohol Treatment
    Article

    Caplan et al. on Civil Commitment for Alcohol Treatment

    Art Caplan and his co-authors have a new piece out in the Lancet on the possibility of using civil commitment and compulsory treatment for those with grave alcohol use disorders.  Take a look here.

  • Read more: Of Evergreening and Efficacy, Part II
    Article

    Of Evergreening and Efficacy, Part II

    By Ryan Abbott I wrote earlier this month about the case between Novartis and the Union of India, in which the Supreme Court of India affirmed denying a patent for Novartis’ anti-cancer drug Glivec. Adriana Benedict added an insightful post about the case last week. In my last post, I talked about the theory behind the decision and…

  • Read more: Twitter Round-Up (3/31-4/6)
    Article

    Twitter Round-Up (3/31-4/6)

    By Casey Thomson This week’s slightly belated round-up concerns palliative care across cultures, the threat and problems of over-prescribing, and Big Pharma’s failure to create prices with the patient in mind. Read on for more from this week’s round-up. Alex Smith (@AlexSmithMD) retweeted a piece on the lessons learned by Dr. Vvjeyanthi “V.J.” Periyakoil on…

  • Read more: If Novartis’s “improved” version of Glivec is not more therapeutically efficacious, why is the Novartis decision such a big deal?
    Article

    If Novartis’s “improved” version of Glivec is not more therapeutically efficacious, why is the Novartis decision such a big deal?

    By Adriana Benedict Last week, Ryan Abbot blogged here about the Novartis case decided last Monday by the Supreme Court of India.  Since then, there have been a broad range of reactions to the case, but many of them appear to have left a lurking elephant in the room. I’d like to attempt to provide…

  • Read more: Public Health Protection under the EPA Lead and Copper Rule
    Article

    Public Health Protection under the EPA Lead and Copper Rule

     By Dr. Yanna Lambrinidou and Dr. Marc Edwards It is generally safe to assume that, when it comes to contaminants in drinking water, consumers are protected by regulation and proactive water utilities. One noteworthy exception is the federal law promulgated to protect the public from lead at the tap. Known as the Lead and Copper…

  • Read more: Happy Public Health Week: “We’re Good Enough, We’re Smart Enough, and Doggone It, People Like Us”
    Article

    Happy Public Health Week: “We’re Good Enough, We’re Smart Enough, and Doggone It, People Like Us”

    By Scott Burris We may be living in a golden age of group-think. A weekly reminder is poor Paul Krugman railing against the apparently universal belief in America and Europe that we’ve got to cut budgets right now or disaster will strike. He calls this a Zombie idea, a false claim that has been falsified…

  • Read more: Disseminating Where It Matters
    Article

    Disseminating Where It Matters

    By Scott Burris   Public Health Law Research funded Dr. Caleb Banta-Green to evaluate the implementation and initial effects of a Washington State “Good Samaritan 911” law meant to encourage people witnessing a drug overdose to call for help. The research results are getting out in the usual way, but it was great to see Dr.…

  • Read more: Harvard HIP (High Impact Philanthropy): Toby Ord speaking tonight
    Article

    Harvard HIP (High Impact Philanthropy): Toby Ord speaking tonight

    Are you interested in foreign aid, global development, medicine? Want to know how philanthropy and charitable giving can do the most good? Aid Works (On Average) – By Toby Ord Tuesday, March 26th; Emerson Hall 108; 8 PM There is considerable controversy about whether foreign aid helps poor countries, with several prominent critics arguing that it doesn’t. Dr. Ord shows that…